Yu Onchee, Bohlke Kari, Hanson Christi A, Delaney Kristin, Rees Thomas G, Zavitkovsky Ann, Ray Paula, Mullooly John, Black Steven B, Benson Patti, Thompson William W, Davis Robert L, Jackson Lisa A
Group Health Center for Health Studies, Seattle, WA 98101-1448, USA.
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):736-45. doi: 10.1002/pds.1354.
Hepatitis B vaccine has been postulated as a possible cause of autoimmune disorders, including autoimmune thyroid diseases (ATD). Cases of Graves' disease and Hashimoto's thyroiditis, following hepatitis B vaccine have been reported to the Vaccine Adverse Events Reporting System (VAERS). To test the hypothesis that hepatitis B vaccine increases the risk of ATD, we conducted a case-control study, within the Vaccine Safety Datalink project.
We identified potential cases of Graves' disease and Hashimoto's thyroiditis, among persons aged 18-69 years from administrative data recorded by three health maintenance organizations (HMOs) and verified cases by medical record review. Controls were frequency-matched to cases by birth year, sex, and study site. Vaccine information was collected from administrative records, chart review, and telephone interviews with study subjects. We enrolled 355 Graves' disease cases, 418 Hashimoto's thyroiditis cases, and 1102 controls. We assessed the association between ever-receipt of hepatitis B vaccine, as well as receipt of hepatitis B vaccine less than 1 year, 1-5 years and at least 5 years prior to the index date, and the risk of ATD.
Ever-receipt of hepatitis B vaccine was not associated with risk of Graves' disease (odds ratio (OR), 0.90; 95% confidence interval (CI), 0.62-1.32) or Hashimoto's thyroiditis (OR, 1.23; 95%CI, 0.87-1.73). There was also no association between the time interval since receipt of hepatitis B vaccination and either outcome.
We did not observe an increased risk of Graves' disease or Hashimoto's thyroiditis, following receipt of hepatitis B vaccine.
乙肝疫苗被认为可能是自身免疫性疾病的一个病因,包括自身免疫性甲状腺疾病(ATD)。已有接种乙肝疫苗后发生格雷夫斯病和桥本甲状腺炎的病例报告至疫苗不良事件报告系统(VAERS)。为验证乙肝疫苗会增加患ATD风险这一假说,我们在疫苗安全数据链项目中开展了一项病例对照研究。
我们从三个健康维护组织(HMO)记录的管理数据中识别出年龄在18至69岁之间的潜在格雷夫斯病和桥本甲状腺炎病例,并通过病历审查核实病例。对照根据出生年份、性别和研究地点与病例进行频率匹配。从管理记录、病历审查以及对研究对象的电话访谈中收集疫苗信息。我们纳入了355例格雷夫斯病病例、418例桥本甲状腺炎病例和1102例对照。我们评估了既往接种乙肝疫苗以及在索引日期前不到1年、1至5年和至少5年接种乙肝疫苗与患ATD风险之间的关联。
既往接种乙肝疫苗与格雷夫斯病风险(比值比(OR),0.90;95%置信区间(CI),0.62 - 1.32)或桥本甲状腺炎风险(OR,1.23;95%CI,0.87 - 1.73)均无关联。接种乙肝疫苗后的时间间隔与任何一种结局之间也无关联。
我们未观察到接种乙肝疫苗后格雷夫斯病或桥本甲状腺炎风险增加。